ABCG2 and hepatocellular carcinoma: Accordingly, gefitinib may not only function as an EGFR inhibitor to block EGFR/HER3 activation and its downstream survival signaling, but also act as a BCRP/ABCG2 inhibitor by reducing its protein expression and pump activity to prevent the sorafenib efflux from HCC cells.